Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AdaptHealth Corp.AHCO · Entity 5183 | CLO and General Counsel | February 26, 2026 | February 27, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AdaptHealth Corp.
Report date February 26, 2026 · Filed February 27, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 107,097 |
Reported balance
After 2026-02-26 transaction · row 1
1 source rowRow 1 · 2026-02-26 · Purchase · Acquired 5,000 · Balance 107,097 |
Past disclosures · reporting ended (3)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
IsoPlexis Corp
Report date March 21, 2023 · Filed March 21, 2023
Section 16 reporting ended · disclosed 2023-03-21. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-03-21 transaction · row 1
1 source rowRow 1 · 2023-03-21 · Disposition to issuer · Disposed 20,000 · Balance 0 F1: On March 21, 2023, pursuant to the Agreement and Plan of Merger, dated as of December 21, 2022 (the Merger Agreement), by and among IsoPlexis Corporation, a Delaware corporation (IsoPlexis), Berkeley Lights, Inc., a Delaware corporation (Berkeley Lights), and Iceland Merger Sub Inc., a Delaware corporation and a wholly owned subsidiary of Berkeley Lights, each share of common stock, par value $0.001, of IsoPlexis (IsoPlexis Common Stock) reported in this Form 4 was converted into the right to receive 0.6120 fully paid and nonassessable shares of common stock, par value $0.00005, of Berkeley Lights (Berkeley Lights Common Stock), together with cash in lieu of fractional shares of Berkeley Lights Common Stock, if any, and any unpaid dividends or other distributions. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $8.02 · Expires 2031-12-06 | Direct | 0 |
Reported balance
After 2023-03-21 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-03-21 · Disposition to issuer · Disposed 40,000 · Balance 0 F2: On March 21, 2023, pursuant to the Merger Agreement, each IsoPlexis stock option (whether vested or unvested) reported in this Form 4 (a) if the per-share exercise price was equal to or greater than the average closing trading price for a share of IsoPlexis Common Stock rounded to the nearest one-tenth of a cent, as reported on The Nasdaq Stock Market LLC for the five most recent trading days ending on and including the third business day prior to March 20, 2023 (the Company Trading Price), was canceled for no consideration and (b) if the per-share exercise price was less than the Company Trading Price, was converted into a Berkeley Lights stock option of approximately equivalent value and generally on the same terms and conditions. F3: Vested 25% on December 6, 2022 and thereafter in 36 equal monthly installments. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $3.43 · Expires 2032-03-31 | Direct | 0 |
Reported balance
After 2023-03-21 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-03-21 · Disposition to issuer · Disposed 101,800 · Balance 0 F2: On March 21, 2023, pursuant to the Merger Agreement, each IsoPlexis stock option (whether vested or unvested) reported in this Form 4 (a) if the per-share exercise price was equal to or greater than the average closing trading price for a share of IsoPlexis Common Stock rounded to the nearest one-tenth of a cent, as reported on The Nasdaq Stock Market LLC for the five most recent trading days ending on and including the third business day prior to March 20, 2023 (the Company Trading Price), was canceled for no consideration and (b) if the per-share exercise price was less than the Company Trading Price, was converted into a Berkeley Lights stock option of approximately equivalent value and generally on the same terms and conditions. F4: Vests 25% on March 31, 2023 and thereafter in 36 equal monthly installments. |
Filing footnotes · ownership attribution and instrument terms
F1: On March 21, 2023, pursuant to the Agreement and Plan of Merger, dated as of December 21, 2022 (the Merger Agreement), by and among IsoPlexis Corporation, a Delaware corporation (IsoPlexis), Berkeley Lights, Inc., a Delaware corporation (Berkeley Lights), and Iceland Merger Sub Inc., a Delaware corporation and a wholly owned subsidiary of Berkeley Lights, each share of common stock, par value $0.001, of IsoPlexis (IsoPlexis Common Stock) reported in this Form 4 was converted into the right to receive 0.6120 fully paid and nonassessable shares of common stock, par value $0.00005, of Berkeley Lights (Berkeley Lights Common Stock), together with cash in lieu of fractional shares of Berkeley Lights Common Stock, if any, and any unpaid dividends or other distributions.
F2: On March 21, 2023, pursuant to the Merger Agreement, each IsoPlexis stock option (whether vested or unvested) reported in this Form 4 (a) if the per-share exercise price was equal to or greater than the average closing trading price for a share of IsoPlexis Common Stock rounded to the nearest one-tenth of a cent, as reported on The Nasdaq Stock Market LLC for the five most recent trading days ending on and including the third business day prior to March 20, 2023 (the Company Trading Price), was canceled for no consideration and (b) if the per-share exercise price was less than the Company Trading Price, was converted into a Berkeley Lights stock option of approximately equivalent value and generally on the same terms and conditions.
F3: Vested 25% on December 6, 2022 and thereafter in 36 equal monthly installments.
F4: Vests 25% on March 31, 2023 and thereafter in 36 equal monthly installments.
LUMINEX CORP
Report date July 14, 2021 · Filed July 15, 2021
Section 16 reporting ended · disclosed 2021-07-15. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2021-07-14 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2021-07-14 · Disposition to issuer · Disposed 20,098 · Balance 27,478 F1: Disposed of pursuant to the Agreement and Plan of Merger, by and among DiaSorin S.p.A., Diagonal Subsidiary Inc. and Luminex Corporation (the "Issuer"), dated April 11, 2021 (the "Merger Agreement"), whereby each outstanding share of the Issuer's common stock was cancelled at the effective time (the "Effective Time") of the merger (the "Merger") and converted into the right to receive a cash payment of $37.00 per share. F2: This amount includes 290 shares obtained under the Luminex Corporation Employee Stock Purchase Plan on May 31, 2021, and 14 shares acquired from the Reporting Person's brokerage Dividend Reinvestment Plan as follows: 7 shares on April 15, 2021 and 7 shares on July 8, 2021. Row 2 · 2021-07-14 · Disposition to issuer · Disposed 27,478 · Balance 0 F3: Disposed of pursuant to the Merger Agreement, whereby unvested shares of restricted stock which were outstanding as of immediately prior to the Effective Time fully vested and became unrestricted common stock, and each such share of common stock that was outstanding immediately prior to the Effective Time was canceled at the Effective Time, in exchange for cash payments in the amount of $37.00 per share (without interest and subject to deduction for any required withholding taxes). |
| Stock Option (Right To Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.93 · Expires 2022-03-11 | Direct | 0 |
Reported balance
After 2021-07-14 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-07-14 · Disposition to issuer · Disposed 11,176 · Balance 0 F4: Disposed of pursuant to the Merger Agreement, whereby each stock option outstanding as of immediately prior to the Effective Time fully vested and was cancelled at the Effective Time and converted into the right to receive a total amount in cash, equal to the product of (x) the excess, if any, of $37.00 over the exercise price per share of each stock option (without interest and subject to deduction for any required withholding taxes) and (y) the number of shares underlying such stock option. If the amount that could have been obtained upon the exercise of the stock option pursuant to the foregoing is equal to or less than zero, then the option was terminated without payment. |
| Stock Option (Right To Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.13 · Expires 2023-03-22 | Direct | 0 |
Reported balance
After 2021-07-14 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-07-14 · Disposition to issuer · Disposed 17,430 · Balance 0 F4: Disposed of pursuant to the Merger Agreement, whereby each stock option outstanding as of immediately prior to the Effective Time fully vested and was cancelled at the Effective Time and converted into the right to receive a total amount in cash, equal to the product of (x) the excess, if any, of $37.00 over the exercise price per share of each stock option (without interest and subject to deduction for any required withholding taxes) and (y) the number of shares underlying such stock option. If the amount that could have been obtained upon the exercise of the stock option pursuant to the foregoing is equal to or less than zero, then the option was terminated without payment. |
| Stock Option (Right To Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.13 · Expires 2023-03-22 | Direct | 0 |
Reported balance
After 2021-07-14 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2021-07-14 · Disposition to issuer · Disposed 29,050 · Balance 0 F4: Disposed of pursuant to the Merger Agreement, whereby each stock option outstanding as of immediately prior to the Effective Time fully vested and was cancelled at the Effective Time and converted into the right to receive a total amount in cash, equal to the product of (x) the excess, if any, of $37.00 over the exercise price per share of each stock option (without interest and subject to deduction for any required withholding taxes) and (y) the number of shares underlying such stock option. If the amount that could have been obtained upon the exercise of the stock option pursuant to the foregoing is equal to or less than zero, then the option was terminated without payment. |
| Stock Option (Right To Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.04 · Expires 2024-03-10 | Direct | 0 |
Reported balance
After 2021-07-14 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2021-07-14 · Disposition to issuer · Disposed 58,607 · Balance 0 F4: Disposed of pursuant to the Merger Agreement, whereby each stock option outstanding as of immediately prior to the Effective Time fully vested and was cancelled at the Effective Time and converted into the right to receive a total amount in cash, equal to the product of (x) the excess, if any, of $37.00 over the exercise price per share of each stock option (without interest and subject to deduction for any required withholding taxes) and (y) the number of shares underlying such stock option. If the amount that could have been obtained upon the exercise of the stock option pursuant to the foregoing is equal to or less than zero, then the option was terminated without payment. |
| Stock Option (Right To Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.98 · Expires 2025-03-12 | Direct | 0 |
Reported balance
After 2021-07-14 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2021-07-14 · Disposition to issuer · Disposed 25,697 · Balance 0 F4: Disposed of pursuant to the Merger Agreement, whereby each stock option outstanding as of immediately prior to the Effective Time fully vested and was cancelled at the Effective Time and converted into the right to receive a total amount in cash, equal to the product of (x) the excess, if any, of $37.00 over the exercise price per share of each stock option (without interest and subject to deduction for any required withholding taxes) and (y) the number of shares underlying such stock option. If the amount that could have been obtained upon the exercise of the stock option pursuant to the foregoing is equal to or less than zero, then the option was terminated without payment. |
| Stock Option (Right To Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.43 · Expires 2026-03-12 | Direct | 0 |
Reported balance
After 2021-07-14 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2021-07-14 · Disposition to issuer · Disposed 19,967 · Balance 0 F4: Disposed of pursuant to the Merger Agreement, whereby each stock option outstanding as of immediately prior to the Effective Time fully vested and was cancelled at the Effective Time and converted into the right to receive a total amount in cash, equal to the product of (x) the excess, if any, of $37.00 over the exercise price per share of each stock option (without interest and subject to deduction for any required withholding taxes) and (y) the number of shares underlying such stock option. If the amount that could have been obtained upon the exercise of the stock option pursuant to the foregoing is equal to or less than zero, then the option was terminated without payment. |
| Stock Option (Right To Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.09 · Expires 2027-03-12 | Direct | 0 |
Reported balance
After 2021-07-14 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2021-07-14 · Disposition to issuer · Disposed 66,490 · Balance 0 F4: Disposed of pursuant to the Merger Agreement, whereby each stock option outstanding as of immediately prior to the Effective Time fully vested and was cancelled at the Effective Time and converted into the right to receive a total amount in cash, equal to the product of (x) the excess, if any, of $37.00 over the exercise price per share of each stock option (without interest and subject to deduction for any required withholding taxes) and (y) the number of shares underlying such stock option. If the amount that could have been obtained upon the exercise of the stock option pursuant to the foregoing is equal to or less than zero, then the option was terminated without payment. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to the Agreement and Plan of Merger, by and among DiaSorin S.p.A., Diagonal Subsidiary Inc. and Luminex Corporation (the "Issuer"), dated April 11, 2021 (the "Merger Agreement"), whereby each outstanding share of the Issuer's common stock was cancelled at the effective time (the "Effective Time") of the merger (the "Merger") and converted into the right to receive a cash payment of $37.00 per share.
F2: This amount includes 290 shares obtained under the Luminex Corporation Employee Stock Purchase Plan on May 31, 2021, and 14 shares acquired from the Reporting Person's brokerage Dividend Reinvestment Plan as follows: 7 shares on April 15, 2021 and 7 shares on July 8, 2021.
F3: Disposed of pursuant to the Merger Agreement, whereby unvested shares of restricted stock which were outstanding as of immediately prior to the Effective Time fully vested and became unrestricted common stock, and each such share of common stock that was outstanding immediately prior to the Effective Time was canceled at the Effective Time, in exchange for cash payments in the amount of $37.00 per share (without interest and subject to deduction for any required withholding taxes).
F4: Disposed of pursuant to the Merger Agreement, whereby each stock option outstanding as of immediately prior to the Effective Time fully vested and was cancelled at the Effective Time and converted into the right to receive a total amount in cash, equal to the product of (x) the excess, if any, of $37.00 over the exercise price per share of each stock option (without interest and subject to deduction for any required withholding taxes) and (y) the number of shares underlying such stock option. If the amount that could have been obtained upon the exercise of the stock option pursuant to the foregoing is equal to or less than zero, then the option was terminated without payment.
Tabula Rasa HealthCare, Inc.
Report date November 03, 2023 · Filed November 14, 2023
Section 16 reporting ended · disclosed 2023-11-14. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2023-11-03 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2023-11-03 · Disposition to issuer · Disposed 25,463 · Balance 38,194 F1: Upon the consummation of the merger (the "Merger") contemplated by that certain Agreement and Plan of Merger, by and among Tabula Rasa HealthCare, Inc. (the "Company"), Locke Buyer, LLC and Locke Merger Sub, Inc., dated August 5, 2023 (the "Merger Agreement"), 25,463 outstanding restricted stock units ("RSUs") were cancelled and converted into the right to receive a cash payment of $267,361.50, representing the product obtained by multiplying (x) the aggregate number of shares of common stock of the Company ("Common Stock") underlying the RSUs, by (y) the offer price ($10.50). Row 2 · 2023-11-03 · Disposition to issuer · Disposed 38,194 · Balance 0 F2: Represents 38,194 shares of Common Stock underlying performance stock units ("PSUs") that were vested as of immediately prior to the effective time of the Merger but not yet settled or that automatically vested as a result of the Merger in accordance with their terms and without the exercise of discretion. The PSUs were not previously reported as the number of shares underlying the PSUs was not determinable. Pursuant to the terms of the Merger Agreement, the PSUs were cancelled in the Merger and converted into the right to receive a cash payment of $401,037, representing the product obtained by multiplying (x) the aggregate number of shares of Common Stock issuable in settlement of the PSUs, by (y) the offer price ($10.50). |
Filing footnotes · ownership attribution and instrument terms
F1: Upon the consummation of the merger (the "Merger") contemplated by that certain Agreement and Plan of Merger, by and among Tabula Rasa HealthCare, Inc. (the "Company"), Locke Buyer, LLC and Locke Merger Sub, Inc., dated August 5, 2023 (the "Merger Agreement"), 25,463 outstanding restricted stock units ("RSUs") were cancelled and converted into the right to receive a cash payment of $267,361.50, representing the product obtained by multiplying (x) the aggregate number of shares of common stock of the Company ("Common Stock") underlying the RSUs, by (y) the offer price ($10.50).
F2: Represents 38,194 shares of Common Stock underlying performance stock units ("PSUs") that were vested as of immediately prior to the effective time of the Merger but not yet settled or that automatically vested as a result of the Merger in accordance with their terms and without the exercise of discretion. The PSUs were not previously reported as the number of shares underlying the PSUs was not determinable. Pursuant to the terms of the Merger Agreement, the PSUs were cancelled in the Merger and converted into the right to receive a cash payment of $401,037, representing the product obtained by multiplying (x) the aggregate number of shares of Common Stock issuable in settlement of the PSUs, by (y) the offer price ($10.50).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 26, 2026 Filed Feb 27, 2026 16:01 UTC | AdaptHealth Corp. AHCO · Entity 5183 | PurchaseCommon Stock | 5,000 | $8.91 | $44,550.00 |
DisclosureSEC source: 0001104659-26-021535 · tm267540-1_4seq1.xml · nonDerivative · entry 1 Rew Richard W. II · CIK 0001433265 · CLO and General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 107,097 Read SEC document |
| January 30, 2026 Filed Feb 3, 2026 20:24 UTC | AdaptHealth Corp. AHCO · Entity 5183 | GrantCommon Stock | 53,688 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-009929 · tm264996-8_4seq1.xml · nonDerivative · entry 1 Rew Richard W. II · CIK 0001433265 · CLO and General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 102,097 F1 · shares: These shares represent restricted stock units and will be settled in common stock upon vesting. F1 · price: These shares represent restricted stock units and will be settled in common stock upon vesting. Read SEC document |
| February 01, 2025 Filed Feb 4, 2025 16:30 UTC | AdaptHealth Corp. AHCO · Entity 5183 | GrantCommon Stock | 48,409 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-009140 · tm255363-7_4seq1.xml · nonDerivative · entry 1 Rew Richard W. II · CIK 0001433265 · CLO and General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,409 F1 · shares: These shares represent restricted stock units and will be settled in common stock upon vesting. F1 · price: These shares represent restricted stock units and will be settled in common stock upon vesting. Read SEC document |
| November 03, 2023 Filed Nov 14, 2023 18:08 UTC | Tabula Rasa HealthCare, Inc. TRHC · Entity 108300 | Disposition to issuerCommon Stock | 38,194 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-23-015110 · form4-11142023_111147.xml · nonDerivative · entry 2 Rew Richard W. II · CIK 0001433265 · CHIEF LEGAL OFFICER, SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F2 · price: Represents 38,194 shares of Common Stock underlying performance stock units ("PSUs") that were vested as of immediately prior to the effective time of the Merger but not yet settled or that automatically vested as a result of the Merger in accordance with their terms and without the exercise of discretion. The PSUs were not previously reported as the number of shares underlying the PSUs was not determinable. Pursuant to the terms of the Merger Agreement, the PSUs were cancelled in the Merger and converted into the right to receive a cash payment of $401,037, representing the product obtained by multiplying (x) the aggregate number of shares of Common Stock issuable in settlement of the PSUs, by (y) the offer price ($10.50). Read SEC document |
| November 03, 2023 Filed Nov 14, 2023 18:08 UTC | Tabula Rasa HealthCare, Inc. TRHC · Entity 108300 | Disposition to issuerCommon Stock | 25,463 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-23-015110 · form4-11142023_111147.xml · nonDerivative · entry 1 Rew Richard W. II · CIK 0001433265 · CHIEF LEGAL OFFICER, SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,194 F1 · price: Upon the consummation of the merger (the "Merger") contemplated by that certain Agreement and Plan of Merger, by and among Tabula Rasa HealthCare, Inc. (the "Company"), Locke Buyer, LLC and Locke Merger Sub, Inc., dated August 5, 2023 (the "Merger Agreement"), 25,463 outstanding restricted stock units ("RSUs") were cancelled and converted into the right to receive a cash payment of $267,361.50, representing the product obtained by multiplying (x) the aggregate number of shares of common stock of the Company ("Common Stock") underlying the RSUs, by (y) the offer price ($10.50). Read SEC document |
| April 19, 2023 Filed Apr 21, 2023 17:26 UTC | Tabula Rasa HealthCare, Inc. TRHC · Entity 108300 | GrantCommon Stock | 25,463 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-006790 · form4-04212023_090455.xml · nonDerivative · entry 1 Rew Richard W. II · CIK 0001433265 · CHIEF LEGAL OFFICER, SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,463 F1 · kind: Grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. Read SEC document |
| March 21, 2023 Filed Mar 21, 2023 16:45 UTC | IsoPlexis Corp ISO · Entity 115290 | Disposition to issuerStock Option · Derivative | 101,800 | Not disclosed Strike: $3.43 | Not disclosed |
DisclosureSEC source: 0001062993-23-007397 · form4.xml · derivative · entry 3 Rew Richard W. II · CIK 0001433265 · SVP, GC and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 101,800 shares Expires 2032-03-31 F2 · price: On March 21, 2023, pursuant to the Merger Agreement, each IsoPlexis stock option (whether vested or unvested) reported in this Form 4 (a) if the per-share exercise price was equal to or greater than the average closing trading price for a share of IsoPlexis Common Stock rounded to the nearest one-tenth of a cent, as reported on The Nasdaq Stock Market LLC for the five most recent trading days ending on and including the third business day prior to March 20, 2023 (the Company Trading Price), was canceled for no consideration and (b) if the per-share exercise price was less than the Company Trading Price, was converted into a Berkeley Lights stock option of approximately equivalent value and generally on the same terms and conditions. F4 · derivative.exercise_date: Vests 25% on March 31, 2023 and thereafter in 36 equal monthly installments. Read SEC document |
| March 21, 2023 Filed Mar 21, 2023 16:45 UTC | IsoPlexis Corp ISO · Entity 115290 | Disposition to issuerStock Option · Derivative | 40,000 | Not disclosed Strike: $8.02 | Not disclosed |
DisclosureSEC source: 0001062993-23-007397 · form4.xml · derivative · entry 2 Rew Richard W. II · CIK 0001433265 · SVP, GC and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,000 shares Expires 2031-12-06 F2 · price: On March 21, 2023, pursuant to the Merger Agreement, each IsoPlexis stock option (whether vested or unvested) reported in this Form 4 (a) if the per-share exercise price was equal to or greater than the average closing trading price for a share of IsoPlexis Common Stock rounded to the nearest one-tenth of a cent, as reported on The Nasdaq Stock Market LLC for the five most recent trading days ending on and including the third business day prior to March 20, 2023 (the Company Trading Price), was canceled for no consideration and (b) if the per-share exercise price was less than the Company Trading Price, was converted into a Berkeley Lights stock option of approximately equivalent value and generally on the same terms and conditions. F3 · derivative.exercise_date: Vested 25% on December 6, 2022 and thereafter in 36 equal monthly installments. Read SEC document |
| March 21, 2023 Filed Mar 21, 2023 16:45 UTC | IsoPlexis Corp ISO · Entity 115290 | Disposition to issuerCommon Stock | 20,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001062993-23-007397 · form4.xml · nonDerivative · entry 1 Rew Richard W. II · CIK 0001433265 · SVP, GC and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: On March 21, 2023, pursuant to the Agreement and Plan of Merger, dated as of December 21, 2022 (the Merger Agreement), by and among IsoPlexis Corporation, a Delaware corporation (IsoPlexis), Berkeley Lights, Inc., a Delaware corporation (Berkeley Lights), and Iceland Merger Sub Inc., a Delaware corporation and a wholly owned subsidiary of Berkeley Lights, each share of common stock, par value $0.001, of IsoPlexis (IsoPlexis Common Stock) reported in this Form 4 was converted into the right to receive 0.6120 fully paid and nonassessable shares of common stock, par value $0.00005, of Berkeley Lights (Berkeley Lights Common Stock), together with cash in lieu of fractional shares of Berkeley Lights Common Stock, if any, and any unpaid dividends or other distributions. Read SEC document |
| August 25, 2022 Filed Aug 29, 2022 11:07 UTC | IsoPlexis Corp ISO · Entity 115290 | PurchaseCommon Stock | 20,000 | $1.99 | $39,800.00 |
DisclosureSEC source: 0001062993-22-018818 · form4.xml · nonDerivative · entry 1 Rew Richard W. II · CIK 0001433265 · SVP, GC and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.91 to $2.15, inclusive. The reporting person undertakes to provide the issuer, any security holder, or the staff of the SEC, upon request, full information with respect to the foregoing. Read SEC document |
| March 31, 2022 Filed Apr 4, 2022 09:20 UTC | IsoPlexis Corp ISO · Entity 115290 | GrantStock Option · Derivative | 101,800 | $0.00 Strike: $3.43 | $0.00 |
DisclosureSEC source: 0001062993-22-009285 · form4.xml · derivative · entry 1 Rew Richard W. II · CIK 0001433265 · SVP, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,800 Underlying: Common Stock · 101,800 shares Expires 2032-03-31 F1 · derivative.exercise_date: Vests 25% on first anniversary of grant date and thereafter in 36 equal monthly installments. Read SEC document |
| December 06, 2021 Filed Dec 7, 2021 14:52 UTC | IsoPlexis Corp ISO · Entity 115290 | GrantStock Option · Derivative | 40,000 | $0.00 Strike: $8.02 | $0.00 |
DisclosureSEC source: 0001062993-21-012296 · form4.xml · derivative · entry 1 Rew Richard W. II · CIK 0001433265 · SVP, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2031-12-06 F1 · derivative.exercise_date: Vests 25% on first anniversary of grant date and thereafter in 36 equal monthly installments. Read SEC document |
| July 14, 2021 Filed Jul 15, 2021 15:58 UTC | LUMINEX CORP LMNX · Entity 137318 | Disposition to issuerStock Option (Right To Buy) · Derivative | 66,490 | $23.09 Strike: $23.09 | $1,535,254.10 |
DisclosureSEC source: 0001033905-21-000055 · wf-form4_162637911491217.xml · derivative · entry 9 Rew Richard W. II · CIK 0001433265 · SVP, Gen Counsel & Corp Secy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 66,490 shares Expires 2027-03-12 F4 · shares: Disposed of pursuant to the Merger Agreement, whereby each stock option outstanding as of immediately prior to the Effective Time fully vested and was cancelled at the Effective Time and converted into the right to receive a total amount in cash, equal to the product of (x) the excess, if any, of $37.00 over the exercise price per share of each stock option (without interest and subject to deduction for any required withholding taxes) and (y) the number of shares underlying such stock option. If the amount that could have been obtained upon the exercise of the stock option pursuant to the foregoing is equal to or less than zero, then the option was terminated without payment. F4 · price: Disposed of pursuant to the Merger Agreement, whereby each stock option outstanding as of immediately prior to the Effective Time fully vested and was cancelled at the Effective Time and converted into the right to receive a total amount in cash, equal to the product of (x) the excess, if any, of $37.00 over the exercise price per share of each stock option (without interest and subject to deduction for any required withholding taxes) and (y) the number of shares underlying such stock option. If the amount that could have been obtained upon the exercise of the stock option pursuant to the foregoing is equal to or less than zero, then the option was terminated without payment. Read SEC document |
| July 14, 2021 Filed Jul 15, 2021 15:58 UTC | LUMINEX CORP LMNX · Entity 137318 | Disposition to issuerStock Option (Right To Buy) · Derivative | 19,967 | $24.43 Strike: $24.43 | $487,793.81 |
DisclosureSEC source: 0001033905-21-000055 · wf-form4_162637911491217.xml · derivative · entry 8 Rew Richard W. II · CIK 0001433265 · SVP, Gen Counsel & Corp Secy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 19,967 shares Expires 2026-03-12 F4 · shares: Disposed of pursuant to the Merger Agreement, whereby each stock option outstanding as of immediately prior to the Effective Time fully vested and was cancelled at the Effective Time and converted into the right to receive a total amount in cash, equal to the product of (x) the excess, if any, of $37.00 over the exercise price per share of each stock option (without interest and subject to deduction for any required withholding taxes) and (y) the number of shares underlying such stock option. If the amount that could have been obtained upon the exercise of the stock option pursuant to the foregoing is equal to or less than zero, then the option was terminated without payment. F4 · price: Disposed of pursuant to the Merger Agreement, whereby each stock option outstanding as of immediately prior to the Effective Time fully vested and was cancelled at the Effective Time and converted into the right to receive a total amount in cash, equal to the product of (x) the excess, if any, of $37.00 over the exercise price per share of each stock option (without interest and subject to deduction for any required withholding taxes) and (y) the number of shares underlying such stock option. If the amount that could have been obtained upon the exercise of the stock option pursuant to the foregoing is equal to or less than zero, then the option was terminated without payment. Read SEC document |
| July 14, 2021 Filed Jul 15, 2021 15:58 UTC | LUMINEX CORP LMNX · Entity 137318 | Disposition to issuerStock Option (Right To Buy) · Derivative | 25,697 | $21.98 Strike: $21.98 | $564,820.06 |
DisclosureSEC source: 0001033905-21-000055 · wf-form4_162637911491217.xml · derivative · entry 7 Rew Richard W. II · CIK 0001433265 · SVP, Gen Counsel & Corp Secy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,697 shares Expires 2025-03-12 F4 · shares: Disposed of pursuant to the Merger Agreement, whereby each stock option outstanding as of immediately prior to the Effective Time fully vested and was cancelled at the Effective Time and converted into the right to receive a total amount in cash, equal to the product of (x) the excess, if any, of $37.00 over the exercise price per share of each stock option (without interest and subject to deduction for any required withholding taxes) and (y) the number of shares underlying such stock option. If the amount that could have been obtained upon the exercise of the stock option pursuant to the foregoing is equal to or less than zero, then the option was terminated without payment. F4 · price: Disposed of pursuant to the Merger Agreement, whereby each stock option outstanding as of immediately prior to the Effective Time fully vested and was cancelled at the Effective Time and converted into the right to receive a total amount in cash, equal to the product of (x) the excess, if any, of $37.00 over the exercise price per share of each stock option (without interest and subject to deduction for any required withholding taxes) and (y) the number of shares underlying such stock option. If the amount that could have been obtained upon the exercise of the stock option pursuant to the foregoing is equal to or less than zero, then the option was terminated without payment. Read SEC document |
| July 14, 2021 Filed Jul 15, 2021 15:58 UTC | LUMINEX CORP LMNX · Entity 137318 | Disposition to issuerStock Option (Right To Buy) · Derivative | 58,607 | $18.04 Strike: $18.04 | $1,057,270.28 |
DisclosureSEC source: 0001033905-21-000055 · wf-form4_162637911491217.xml · derivative · entry 6 Rew Richard W. II · CIK 0001433265 · SVP, Gen Counsel & Corp Secy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 58,607 shares Expires 2024-03-10 F4 · shares: Disposed of pursuant to the Merger Agreement, whereby each stock option outstanding as of immediately prior to the Effective Time fully vested and was cancelled at the Effective Time and converted into the right to receive a total amount in cash, equal to the product of (x) the excess, if any, of $37.00 over the exercise price per share of each stock option (without interest and subject to deduction for any required withholding taxes) and (y) the number of shares underlying such stock option. If the amount that could have been obtained upon the exercise of the stock option pursuant to the foregoing is equal to or less than zero, then the option was terminated without payment. F4 · price: Disposed of pursuant to the Merger Agreement, whereby each stock option outstanding as of immediately prior to the Effective Time fully vested and was cancelled at the Effective Time and converted into the right to receive a total amount in cash, equal to the product of (x) the excess, if any, of $37.00 over the exercise price per share of each stock option (without interest and subject to deduction for any required withholding taxes) and (y) the number of shares underlying such stock option. If the amount that could have been obtained upon the exercise of the stock option pursuant to the foregoing is equal to or less than zero, then the option was terminated without payment. Read SEC document |
| July 14, 2021 Filed Jul 15, 2021 15:58 UTC | LUMINEX CORP LMNX · Entity 137318 | Disposition to issuerStock Option (Right To Buy) · Derivative | 29,050 | $19.13 Strike: $19.13 | $555,726.50 |
DisclosureSEC source: 0001033905-21-000055 · wf-form4_162637911491217.xml · derivative · entry 5 Rew Richard W. II · CIK 0001433265 · SVP, Gen Counsel & Corp Secy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 29,050 shares Expires 2023-03-22 F4 · shares: Disposed of pursuant to the Merger Agreement, whereby each stock option outstanding as of immediately prior to the Effective Time fully vested and was cancelled at the Effective Time and converted into the right to receive a total amount in cash, equal to the product of (x) the excess, if any, of $37.00 over the exercise price per share of each stock option (without interest and subject to deduction for any required withholding taxes) and (y) the number of shares underlying such stock option. If the amount that could have been obtained upon the exercise of the stock option pursuant to the foregoing is equal to or less than zero, then the option was terminated without payment. F4 · price: Disposed of pursuant to the Merger Agreement, whereby each stock option outstanding as of immediately prior to the Effective Time fully vested and was cancelled at the Effective Time and converted into the right to receive a total amount in cash, equal to the product of (x) the excess, if any, of $37.00 over the exercise price per share of each stock option (without interest and subject to deduction for any required withholding taxes) and (y) the number of shares underlying such stock option. If the amount that could have been obtained upon the exercise of the stock option pursuant to the foregoing is equal to or less than zero, then the option was terminated without payment. Read SEC document |
| July 14, 2021 Filed Jul 15, 2021 15:58 UTC | LUMINEX CORP LMNX · Entity 137318 | Disposition to issuerStock Option (Right To Buy) · Derivative | 17,430 | $19.13 Strike: $19.13 | $333,435.90 |
DisclosureSEC source: 0001033905-21-000055 · wf-form4_162637911491217.xml · derivative · entry 4 Rew Richard W. II · CIK 0001433265 · SVP, Gen Counsel & Corp Secy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,430 shares Expires 2023-03-22 F4 · shares: Disposed of pursuant to the Merger Agreement, whereby each stock option outstanding as of immediately prior to the Effective Time fully vested and was cancelled at the Effective Time and converted into the right to receive a total amount in cash, equal to the product of (x) the excess, if any, of $37.00 over the exercise price per share of each stock option (without interest and subject to deduction for any required withholding taxes) and (y) the number of shares underlying such stock option. If the amount that could have been obtained upon the exercise of the stock option pursuant to the foregoing is equal to or less than zero, then the option was terminated without payment. F4 · price: Disposed of pursuant to the Merger Agreement, whereby each stock option outstanding as of immediately prior to the Effective Time fully vested and was cancelled at the Effective Time and converted into the right to receive a total amount in cash, equal to the product of (x) the excess, if any, of $37.00 over the exercise price per share of each stock option (without interest and subject to deduction for any required withholding taxes) and (y) the number of shares underlying such stock option. If the amount that could have been obtained upon the exercise of the stock option pursuant to the foregoing is equal to or less than zero, then the option was terminated without payment. Read SEC document |
| July 14, 2021 Filed Jul 15, 2021 15:58 UTC | LUMINEX CORP LMNX · Entity 137318 | Disposition to issuerStock Option (Right To Buy) · Derivative | 11,176 | $15.93 Strike: $15.93 | $178,033.68 |
DisclosureSEC source: 0001033905-21-000055 · wf-form4_162637911491217.xml · derivative · entry 3 Rew Richard W. II · CIK 0001433265 · SVP, Gen Counsel & Corp Secy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,176 shares Expires 2022-03-11 F4 · shares: Disposed of pursuant to the Merger Agreement, whereby each stock option outstanding as of immediately prior to the Effective Time fully vested and was cancelled at the Effective Time and converted into the right to receive a total amount in cash, equal to the product of (x) the excess, if any, of $37.00 over the exercise price per share of each stock option (without interest and subject to deduction for any required withholding taxes) and (y) the number of shares underlying such stock option. If the amount that could have been obtained upon the exercise of the stock option pursuant to the foregoing is equal to or less than zero, then the option was terminated without payment. F4 · price: Disposed of pursuant to the Merger Agreement, whereby each stock option outstanding as of immediately prior to the Effective Time fully vested and was cancelled at the Effective Time and converted into the right to receive a total amount in cash, equal to the product of (x) the excess, if any, of $37.00 over the exercise price per share of each stock option (without interest and subject to deduction for any required withholding taxes) and (y) the number of shares underlying such stock option. If the amount that could have been obtained upon the exercise of the stock option pursuant to the foregoing is equal to or less than zero, then the option was terminated without payment. Read SEC document |
| July 14, 2021 Filed Jul 15, 2021 15:58 UTC | LUMINEX CORP LMNX · Entity 137318 | Disposition to issuerCommon Stock | 27,478 | $37.00 | $1,016,686.00 |
DisclosureSEC source: 0001033905-21-000055 · wf-form4_162637911491217.xml · nonDerivative · entry 2 Rew Richard W. II · CIK 0001433265 · SVP, Gen Counsel & Corp Secy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F3 · shares: Disposed of pursuant to the Merger Agreement, whereby unvested shares of restricted stock which were outstanding as of immediately prior to the Effective Time fully vested and became unrestricted common stock, and each such share of common stock that was outstanding immediately prior to the Effective Time was canceled at the Effective Time, in exchange for cash payments in the amount of $37.00 per share (without interest and subject to deduction for any required withholding taxes). Read SEC document |
| July 14, 2021 Filed Jul 15, 2021 15:58 UTC | LUMINEX CORP LMNX · Entity 137318 | Disposition to issuerCommon Stock | 20,098 | $37.00 | $743,626.00 |
DisclosureSEC source: 0001033905-21-000055 · wf-form4_162637911491217.xml · nonDerivative · entry 1 Rew Richard W. II · CIK 0001433265 · SVP, Gen Counsel & Corp Secy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,478 F1 · shares: Disposed of pursuant to the Agreement and Plan of Merger, by and among DiaSorin S.p.A., Diagonal Subsidiary Inc. and Luminex Corporation (the "Issuer"), dated April 11, 2021 (the "Merger Agreement"), whereby each outstanding share of the Issuer's common stock was cancelled at the effective time (the "Effective Time") of the merger (the "Merger") and converted into the right to receive a cash payment of $37.00 per share. F2 · shares: This amount includes 290 shares obtained under the Luminex Corporation Employee Stock Purchase Plan on May 31, 2021, and 14 shares acquired from the Reporting Person's brokerage Dividend Reinvestment Plan as follows: 7 shares on April 15, 2021 and 7 shares on July 8, 2021. Read SEC document |
| March 12, 2021 Filed Mar 15, 2021 16:51 UTC | LUMINEX CORP LMNX · Entity 137318 | GrantStock Option (Right To Buy) · Derivative | 66,490 | $23.09 Strike: $23.09 | $1,535,254.10 |
DisclosureSEC source: 0001033905-21-000019 · wf-form4_161584149336107.xml · derivative · entry 4 Rew Richard W. II · CIK 0001433265 · SVP, Gen Counsel & Corp Secy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,490 Underlying: Common Stock · 66,490 shares Expires 2027-03-12 F4 · shares: The Board of Directors of Luminex Corporation determined the level of performance and number of shares earned for this performance option. The option will vest annually in four equal installments beginning 03/12/21. Read SEC document |
| March 12, 2021 Filed Mar 15, 2021 16:51 UTC | LUMINEX CORP LMNX · Entity 137318 | GrantCommon Stock | 14,957 | $32.76 | $489,991.32 |
DisclosureSEC source: 0001033905-21-000019 · wf-form4_161584149336107.xml · nonDerivative · entry 3 Rew Richard W. II · CIK 0001433265 · SVP, Gen Counsel & Corp Secy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,272 F3 · balance_after: This balance includes a total of 298 shares obtained November 30, 2020 under the Luminex Corporation Employee Stock Purchase Plan, and 124 shares obtained under a personal dividend reinvestment plan. Read SEC document |
| March 12, 2021 Filed Mar 15, 2021 16:51 UTC | LUMINEX CORP LMNX · Entity 137318 | Tax withholdingCommon Stock | 965 | $32.76 | $31,613.40 |
DisclosureSEC source: 0001033905-21-000019 · wf-form4_161584149336107.xml · nonDerivative · entry 2 Rew Richard W. II · CIK 0001433265 · SVP, Gen Counsel & Corp Secy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,893 F2 · shares: This disposition relates to withholding for taxes on 6,188 vesting shares associated with a previously reported issuance. Read SEC document |
| March 11, 2021 Filed Mar 15, 2021 16:51 UTC | LUMINEX CORP LMNX · Entity 137318 | Tax withholdingCommon Stock | 295 | $32.45 | $9,572.75 |
DisclosureSEC source: 0001033905-21-000019 · wf-form4_161584149336107.xml · nonDerivative · entry 1 Rew Richard W. II · CIK 0001433265 · SVP, Gen Counsel & Corp Secy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,858 F1 · shares: This disposition relates to withholding for taxes on 1,213 vesting shares associated with a previously reported issuance. Read SEC document |
| August 05, 2020 Filed Aug 5, 2020 18:55 UTC | LUMINEX CORP LMNX · Entity 137318 | Exercise / conversionStock Option (Right To Buy) · Derivative | 11,176 | $15.93 Strike: $15.93 | $178,033.68 |
DisclosureSEC source: 0001033905-20-000115 · wf-form4_159666808596116.xml · derivative · entry 9 Rew Richard W. II · CIK 0001433265 · SVP, Gen Counsel & Corp Secy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,176 Underlying: Common Stock · 11,176 shares Expires 2022-03-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 05, 2020 Filed Aug 5, 2020 18:55 UTC | LUMINEX CORP LMNX · Entity 137318 | SaleCommon Stock | 11,176 | $40.93 | $457,433.68 |
DisclosureSEC source: 0001033905-20-000115 · wf-form4_159666808596116.xml · nonDerivative · entry 6 Rew Richard W. II · CIK 0001433265 · SVP, Gen Counsel & Corp Secy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,153 F1 · shares: This sale is being made pursuant to a trading plan intended to comply with Rule 10b5-1 adopted by the seller on May 22, 2020. The representation regarding the seller's knowledge of material adverse non-public information speaks as of the date that the aforementioned trading plan was adopted. Read SEC document |
| August 05, 2020 Filed Aug 5, 2020 18:55 UTC | LUMINEX CORP LMNX · Entity 137318 | Exercise / conversionCommon Stock | 11,176 | $15.93 | $178,033.68 |
DisclosureSEC source: 0001033905-20-000115 · wf-form4_159666808596116.xml · nonDerivative · entry 5 Rew Richard W. II · CIK 0001433265 · SVP, Gen Counsel & Corp Secy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,329 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 04, 2020 Filed Aug 5, 2020 18:55 UTC | LUMINEX CORP LMNX · Entity 137318 | Exercise / conversionStock Option (Right To Buy) · Derivative | 3,786 | $15.93 Strike: $15.93 | $60,310.98 |
DisclosureSEC source: 0001033905-20-000115 · wf-form4_159666808596116.xml · derivative · entry 8 Rew Richard W. II · CIK 0001433265 · SVP, Gen Counsel & Corp Secy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,352 Underlying: Common Stock · 3,786 shares Expires 2022-03-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 04, 2020 Filed Aug 5, 2020 18:55 UTC | LUMINEX CORP LMNX · Entity 137318 | SaleCommon Stock | 3,786 | $38.93 | $147,388.98 |
DisclosureSEC source: 0001033905-20-000115 · wf-form4_159666808596116.xml · nonDerivative · entry 4 Rew Richard W. II · CIK 0001433265 · SVP, Gen Counsel & Corp Secy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,153 F1 · shares: This sale is being made pursuant to a trading plan intended to comply with Rule 10b5-1 adopted by the seller on May 22, 2020. The representation regarding the seller's knowledge of material adverse non-public information speaks as of the date that the aforementioned trading plan was adopted. Read SEC document |
| August 04, 2020 Filed Aug 5, 2020 18:55 UTC | LUMINEX CORP LMNX · Entity 137318 | Exercise / conversionCommon Stock | 3,786 | $15.93 | $60,310.98 |
DisclosureSEC source: 0001033905-20-000115 · wf-form4_159666808596116.xml · nonDerivative · entry 3 Rew Richard W. II · CIK 0001433265 · SVP, Gen Counsel & Corp Secy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,939 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 18:55 UTC | LUMINEX CORP LMNX · Entity 137318 | Exercise / conversionStock Option (Right To Buy) · Derivative | 7,389 | $15.93 Strike: $15.93 | $117,706.77 |
DisclosureSEC source: 0001033905-20-000115 · wf-form4_159666808596116.xml · derivative · entry 7 Rew Richard W. II · CIK 0001433265 · SVP, Gen Counsel & Corp Secy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,138 Underlying: Common Stock · 7,389 shares Expires 2022-03-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 18:55 UTC | LUMINEX CORP LMNX · Entity 137318 | SaleCommon Stock | 7,389 | $38.93 | $287,653.77 |
DisclosureSEC source: 0001033905-20-000115 · wf-form4_159666808596116.xml · nonDerivative · entry 2 Rew Richard W. II · CIK 0001433265 · SVP, Gen Counsel & Corp Secy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,153 F1 · shares: This sale is being made pursuant to a trading plan intended to comply with Rule 10b5-1 adopted by the seller on May 22, 2020. The representation regarding the seller's knowledge of material adverse non-public information speaks as of the date that the aforementioned trading plan was adopted. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 18:55 UTC | LUMINEX CORP LMNX · Entity 137318 | Exercise / conversionCommon Stock | 7,389 | $15.93 | $117,706.77 |
DisclosureSEC source: 0001033905-20-000115 · wf-form4_159666808596116.xml · nonDerivative · entry 1 Rew Richard W. II · CIK 0001433265 · SVP, Gen Counsel & Corp Secy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,542 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 17, 2020 Filed Jul 17, 2020 21:02 UTC | LUMINEX CORP LMNX · Entity 137318 | Exercise / conversionStock Option (Right To Buy) · Derivative | 11,175 | $15.93 Strike: $15.93 | $178,017.75 |
DisclosureSEC source: 0001033905-20-000099 · wf-form4_159503414310252.xml · derivative · entry 3 Rew Richard W. II · CIK 0001433265 · SVP, Gen Counsel & Corp Secy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,527 Underlying: Common Stock · 11,175 shares Expires 2022-03-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 17, 2020 Filed Jul 17, 2020 21:02 UTC | LUMINEX CORP LMNX · Entity 137318 | SaleCommon Stock | 11,175 | $36.93 | $412,692.75 |
DisclosureSEC source: 0001033905-20-000099 · wf-form4_159503414310252.xml · nonDerivative · entry 2 Rew Richard W. II · CIK 0001433265 · SVP, Gen Counsel & Corp Secy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,153 F1 · shares: This sale is being made pursuant to a trading plan intended to comply with Rule 10b5-1 adopted by the seller on May 22, 2020. The representation regarding the seller's knowledge of material adverse non-public information speaks as of the date that the aforementioned trading plan was adopted. F2 · balance_after: This balance includes a total of 344 shares obtained under the Luminex Corporation Employee Stock Purchase Plan on May 29, 2020. Read SEC document |
| July 17, 2020 Filed Jul 17, 2020 21:02 UTC | LUMINEX CORP LMNX · Entity 137318 | Exercise / conversionCommon Stock | 11,175 | $15.93 | $178,017.75 |
DisclosureSEC source: 0001033905-20-000099 · wf-form4_159503414310252.xml · nonDerivative · entry 1 Rew Richard W. II · CIK 0001433265 · SVP, Gen Counsel & Corp Secy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,984 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 12, 2020 Filed Mar 13, 2020 16:29 UTC | LUMINEX CORP LMNX · Entity 137318 | GrantCommon Stock | 8,878 | $23.09 | $204,993.02 |
DisclosureSEC source: 0001033905-20-000025 · wf-form4_158413136432033.xml · nonDerivative · entry 3 Rew Richard W. II · CIK 0001433265 · SVP, Gen Counsel & Corp Secy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,809 F3 · balance_after: This balance includes a total of 670 shares obtained under the Luminex Corporation Employee Stock Purchase Plan. 335 shares obtained May 31, 2019 and 335 shares obtained November 29, 2019. Read SEC document |
| March 12, 2020 Filed Mar 13, 2020 16:29 UTC | LUMINEX CORP LMNX · Entity 137318 | Tax withholdingCommon Stock | 965 | $23.09 | $22,281.85 |
DisclosureSEC source: 0001033905-20-000025 · wf-form4_158413136432033.xml · nonDerivative · entry 2 Rew Richard W. II · CIK 0001433265 · SVP, Gen Counsel & Corp Secy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,261 F2 · shares: This disposition relates to withholding for taxes on 3,969 vesting shares associated with a previously reported issuance. Read SEC document |
| March 11, 2020 Filed Mar 13, 2020 16:29 UTC | LUMINEX CORP LMNX · Entity 137318 | GrantStock Option (Right To Buy) · Derivative | 19,967 | $24.43 Strike: $24.43 | $487,793.81 |
DisclosureSEC source: 0001033905-20-000025 · wf-form4_158413136432033.xml · derivative · entry 4 Rew Richard W. II · CIK 0001433265 · SVP, Gen Counsel & Corp Secy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,967 Underlying: Common Stock · 19,967 shares Expires 2026-03-12 F4 · shares: The Board of Directors of Luminex Corporation determined the level of performance and number of shares earned for this performance option. The option will vest annually in four equal installments beginning 03/12/2020. Read SEC document |
| March 11, 2020 Filed Mar 13, 2020 16:29 UTC | LUMINEX CORP LMNX · Entity 137318 | Tax withholdingCommon Stock | 295 | $27.11 | $7,997.45 |
DisclosureSEC source: 0001033905-20-000025 · wf-form4_158413136432033.xml · nonDerivative · entry 1 Rew Richard W. II · CIK 0001433265 · SVP, Gen Counsel & Corp Secy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,226 F1 · shares: This disposition relates to withholding for taxes on 1,213 vesting shares associated with a previously reported issuance. Read SEC document |
| March 12, 2019 Filed Mar 14, 2019 17:25 UTC | LUMINEX CORP LMNX · Entity 137318 | GrantStock Option (Right To Buy) · Derivative | 25,697 | $21.98 Strike: $21.98 | $564,820.06 |
DisclosureSEC source: 0001033905-19-000024 · wf-form4_155259869553189.xml · derivative · entry 4 Rew Richard W. II · CIK 0001433265 · SVP, Gen Counsel & Corp Secy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,697 Underlying: Common Stock · 25,697 shares Expires 2025-03-12 F4 · shares: The Board of Directors of Luminex Corporation determined the level of performance and number of shares earned for this performance option. The option will vest annually in four equal installments beginning 03/12/19. Read SEC document |
| March 12, 2019 Filed Mar 14, 2019 17:25 UTC | LUMINEX CORP LMNX · Entity 137318 | GrantCommon Stock | 7,572 | $24.43 | $184,983.96 |
DisclosureSEC source: 0001033905-19-000024 · wf-form4_155259869553189.xml · nonDerivative · entry 3 Rew Richard W. II · CIK 0001433265 · SVP, Gen Counsel & Corp Secy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,521 F3 · balance_after: This balance includes a total of 580 shares obtained under the Luminex Corporation Employee Stock Purchase Plan. 333 shares obtained May 31, 2018 and 247 shares obtained November 30, 2018. Read SEC document |
| March 12, 2019 Filed Mar 14, 2019 17:25 UTC | LUMINEX CORP LMNX · Entity 137318 | Tax withholdingCommon Stock | 505 | $24.43 | $12,337.15 |
DisclosureSEC source: 0001033905-19-000024 · wf-form4_155259869553189.xml · nonDerivative · entry 2 Rew Richard W. II · CIK 0001433265 · SVP, Gen Counsel & Corp Secy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,369 F2 · shares: This disposition relates to withholding for taxes on 2,075 vesting shares associated with a previously reported issuance. Read SEC document |
| March 11, 2019 Filed Mar 14, 2019 17:25 UTC | LUMINEX CORP LMNX · Entity 137318 | Tax withholdingCommon Stock | 295 | $24.14 | $7,121.30 |
DisclosureSEC source: 0001033905-19-000024 · wf-form4_155259869553189.xml · nonDerivative · entry 1 Rew Richard W. II · CIK 0001433265 · SVP, Gen Counsel & Corp Secy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,874 F1 · shares: This disposition relates to withholding for taxes on 1,212 vesting shares associated with a previously reported issuance. Read SEC document |
| March 12, 2018 Filed Mar 15, 2018 11:51 UTC | LUMINEX CORP LMNX · Entity 137318 | GrantCommon Stock | 8,303 | $21.98 | $182,499.94 |
DisclosureSEC source: 0001033905-18-000024 · wf-form4_152112909454573.xml · nonDerivative · entry 2 Rew Richard W. II · CIK 0001433265 · SVP, Gen Counsel & Corp Secy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,169 F2 · balance_after: This balance includes a total of 696 shares obtained under the Luminex Corporation Employee Stock Purchase Plan. 357 shares obtained May 31, 2017 and 339 shares obtained November 30, 2017. Read SEC document |
| March 11, 2018 Filed Mar 15, 2018 11:51 UTC | LUMINEX CORP LMNX · Entity 137318 | Tax withholdingCommon Stock | 295 | $21.73 | $6,410.35 |
DisclosureSEC source: 0001033905-18-000024 · wf-form4_152112909454573.xml · nonDerivative · entry 1 Rew Richard W. II · CIK 0001433265 · SVP, Gen Counsel & Corp Secy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,170 F1 · shares: This disposition relates to withholding for taxes on 1,212 vesting shares associated with a previously reported issuance. Read SEC document |
| March 10, 2018 Filed Mar 15, 2018 11:51 UTC | LUMINEX CORP LMNX · Entity 137318 | GrantStock Option (Right To Buy) · Derivative | 58,607 | $18.04 Strike: $18.04 | $1,057,270.28 |
DisclosureSEC source: 0001033905-18-000024 · wf-form4_152112909454573.xml · derivative · entry 3 Rew Richard W. II · CIK 0001433265 · SVP, Gen Counsel & Corp Secy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,607 Underlying: Common Stock · 58,607 shares Expires 2024-03-10 F3 · shares: The Board of Directors of Luminex Corporation determined the level of performance and the number of shares earned for this performance option. The option will vest in four equal installments on the first, second, third and fourth anniversary of the 03/10/2017 grant date. Read SEC document |
| March 10, 2017 Filed Mar 14, 2017 16:02 UTC | LUMINEX CORP LMNX · Entity 137318 | GrantCommon Stock | 4,850 | $0.00 | $0.00 |
DisclosureSEC source: 0001033905-17-000038 · wf-form4_148952173703548.xml · nonDerivative · entry 1 Rew Richard W. II · CIK 0001433265 · SVP, Gen Counsel & Corp Secy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,465 Read SEC document |
| February 24, 2017 Filed Feb 28, 2017 12:46 UTC | LUMINEX CORP LMNX · Entity 137318 | GrantStock Option (Right To Buy) · Derivative | 17,430 | $0.00 Strike: $19.13 | $0.00 |
DisclosureSEC source: 0001033905-17-000030 · wf-form4_148830399315256.xml · derivative · entry 2 Rew Richard W. II · CIK 0001433265 · SVP, Gen Counsel & Corp Secy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,430 Underlying: Common Stock · 17,430 shares Expires 2023-03-22 F2 · date: On February 24, 2017, the Board of Directors of Luminex Corporation determined the level of performance and the number of shares earned for this performance option. The option will vest in four equal installments on the first, second, third and fourth anniversary of the 3/22/2016 grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.